Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycinsensitive were sensitive to MLN0128 in vitro. MLN0128 inhibite...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hassan, Burhan, Akcakanat, Argun, Sangai, Takafumi, Evans, Kurt W., Adkins, Farrell, Eterovic, Agda Karina, Zhao, Hao, Chen, Ken, Chen, Huiqin, Do, Kim-Anh, Xie, Shelly M., Holder, Ashley M., Naing, Aung, Mills, Gordon B., Meric-Bernstam, Funda
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226703/
https://ncbi.nlm.nih.gov/pubmed/25261369
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados